Despite significant improvements in systemic chemotherapy during the past two decades, the prognosis of patients with advanced gastric and gastroesophageal junction adenocarcinoma remains poor. Because of molecular heterogeneity, it is essential to classify tumors based on the underlying oncogenic pathways and to develop targeted therapies acting on individual tumors. Unfortunately, although a number of molecular targets have been studied, very few of these agents can be used in a clinical setting. In this review, we summarize the available data on anti-angiogenic agents in advanced/metastatic gastric cancer.
Angiogenesis inhibitors in gastric and gastroesophageal junction cancer / ROVIELLO, GIANDOMENICO; PETRIOLI, ROBERTO; Marano, Luigi; POLOM, KAROL ROMAN; MARRELLI, DANIELE; PERRELLA, ARMANDO; ROVIELLO, FRANCO. - In: GASTRIC CANCER. - ISSN 1436-3291. - STAMPA. - 19:(2016), pp. 31-41. [10.1007/s10120-015-0537-5]
Angiogenesis inhibitors in gastric and gastroesophageal junction cancer
ROVIELLO, GIANDOMENICO;PERRELLA, ARMANDO;
2016
Abstract
Despite significant improvements in systemic chemotherapy during the past two decades, the prognosis of patients with advanced gastric and gastroesophageal junction adenocarcinoma remains poor. Because of molecular heterogeneity, it is essential to classify tumors based on the underlying oncogenic pathways and to develop targeted therapies acting on individual tumors. Unfortunately, although a number of molecular targets have been studied, very few of these agents can be used in a clinical setting. In this review, we summarize the available data on anti-angiogenic agents in advanced/metastatic gastric cancer.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.pdf
Accesso chiuso
Dimensione
683.9 kB
Formato
Adobe PDF
|
683.9 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
